22246-76-0 Usage
Uses
Used in Pharmaceutical Industry:
8-AMINO-1,3,4,5-TETRAHYDROBENZO[B]AZEPINE-2-ONE is used as a therapeutic agent for the treatment of neurological and psychiatric disorders such as depression and anxiety. Its ability to inhibit monoamine oxidase (MAO) helps regulate neurotransmitter levels, potentially alleviating symptoms associated with these conditions.
Used in Medicinal Chemistry Research:
8-AMINO-1,3,4,5-TETRAHYDROBENZO[B]AZEPINE-2-ONE serves as a tool compound in medicinal chemistry for investigating the physiological and pathological roles of monoamine oxidase (MAO). This research can contribute to a better understanding of the enzyme's function and its implications in various diseases, potentially leading to the development of novel therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 22246-76-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,2,2,4 and 6 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 22246-76:
(7*2)+(6*2)+(5*2)+(4*4)+(3*6)+(2*7)+(1*6)=90
90 % 10 = 0
So 22246-76-0 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N2O/c11-8-5-4-7-2-1-3-10(13)12-9(7)6-8/h4-6H,1-3,11H2,(H,12,13)
22246-76-0Relevant academic research and scientific papers
Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors
Weinberg, Linda R.,Albom, Mark S.,Angeles, Thelma S.,Husten, Jean,Lisko, Joseph G.,McHugh, Robert J.,Milkiewicz, Karen L.,Murthy, Seetha,Ott, Gregory R.,Theroff, Jay P.,Tripathy, Rabindranath,Underiner, Ted L.,Zificsak, Craig A.,Dorsey, Bruce D.
scheme or table, p. 164 - 167 (2011/03/17)
The HGF-c-Met signaling axis is an important paracrine mediator of epithelial-mesenchymal cell interactions involving the regulation of multiple cellular activities including cell motility, mitogenesis, morphogenesis, and angiogenesis. Dysregulation of c-Met signaling (e.g., overexpression or increased activation) is associated with the development of a wide range of tumor types; thus, inhibiting the HGF-c-Met pathway is predicted to lead to anti-tumor effects in many cancers. Elaboration of a 2-arylaminopyrimidine scaffold led to a series of potent c-Met inhibitors bearing a C4-2-amino-N-methylbenzamide group. Specifically, a series of C2-benzazepinone analogs demonstrated potent inhibition of c-Met in enzymatic and cellular assays. Kinase selectivity could be tuned by varying the nature of the alkyl group on the benzazepinone nitrogen.
